Zynerba Pharmaceuticals Inc (ZYNE) stock is higher by 3.77% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
Zynerba Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ZYNE!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ZYNE Stock Today?
Zynerba Pharmaceuticals Inc (ZYNE) stock has fallen -2.62% while the S&P 500 has risen 2.57% as of 3:41 PM on Wednesday, Nov 30. ZYNE is down -$0.01 from the previous closing price of $0.56 on volume of 165,164 shares. Over the past year the S&P 500 is lower by -12.81% while ZYNE is down -84.38%. ZYNE lost -$0.87 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Zynerba Pharmaceuticals Inc click here.
More About Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Click Here to get the full Stock Report for Zynerba Pharmaceuticals Inc stock.